{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:22:16Z","timestamp":1791580936095,"version":"4.3.4"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T00:00:00Z","timestamp":1321833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Specific trials on adult Burkitt lymphoma (BL) and \u2018unclassifiable\u2019 lymphomas with features intermediate between BL and diffuse large B\u2010cell lymphoma (BL\/DLBCL) are advocated which include substantial numbers of older patients, to improve treatment feasibility, while countering risks of systemic and central nervous system (CNS) recurrences. We prospectively evaluated a modified CODOX\u2010M\/IVAC (CODOX\u2010M: cyclophosphamide, vincristine, doxorubicin, high\u2010dose methotrexate; IVAC: ifosfamide, etoposide and high\u2010dose cytarabine) regimen by the addition of rituximab (R) and liposome\u2010encapsulated cytarabine (D) to increase antitumour activity and halve the number of intrathecal treatments. Thirty adults (40% &gt;60\u2003years) with BL (<jats:italic>n<\/jats:italic>\u2003=\u200315) and BL\/DLBCL (<jats:italic>n<\/jats:italic>\u2003=\u200315) were accrued. Primary endpoints were progression\u2010free survival (PFS), CNS recurrence, and liposomal cytarabine\u2010associated toxicity. Eighty percent of patients received the whole treatment programme, the remaining cases received at least three full courses. Application of the RD\u2010CODOX\u2010M\/IVAC regimen resulted in remarkable 4\u2010year PFS (78%) and complete remission (CR) rates (93%). However, PFS was significantly lower in patients older than 60\u2003years as compared to younger ones (49%<jats:italic>vs<\/jats:italic> 93%, <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0\u00b703; median, 36\u2003months), despite high actual dose\u2010intensity, CR rate and tolerability. Reduced\u2010intensity intratechal prophylaxis through liposomal cytarabine was effective because the CNS failure rate was low (3\u00b74%) and without severe neurological toxicities. The RD\u2010CODOX\u2010M\/IVAC strategy is feasible and highly effective, but improving outcomes in elderly patients remains a priority.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08947.x","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T09:19:37Z","timestamp":1321867177000},"page":"234-244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["RD\u2010CODOX\u2010M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B\u2010cell lymphoma"],"prefix":"10.1111","volume":"156","author":[{"given":"Gaetano","family":"Corazzelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Frigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Frairia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Arcamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosaria","family":"De Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Becchimanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Volzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Saggese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Marcacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood.V114.22.1667.1667","article-title":"Rituximab added to CODOX\u2010M\/IVAC has no clear benefit compared to CODOX\u2010M\/IVAC alone in adult patients with Burkitt Lymphoma","volume":"114","author":"Barnes J.A.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"e_1_2_8_5_1","first-page":"3349","article-title":"Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium","volume":"5","author":"Bleyer W.A.","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0405"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1674"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11449"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj994"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005956925637"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi403"},{"key":"e_1_2_8_13_1","first-page":"iv107","article-title":"Myc+ aggressive B\u2010cell lymphomas: novel therapy of untreated Burkitt Lymphoma and Myc+ Diffuse Large B\u2010cell Lymphoma with DA\u2010EPOCH\u2010R","volume":"22","author":"Dunleavy K.","year":"2011","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800597"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2006.02.001"},{"issue":"4","key":"e_1_2_8_18_1","first-page":"iv83","article-title":"Recent results in the treatment of Burkitt lymphomas [abstract]","volume":"19","author":"Hoelzer D.","year":"2008","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_19_1","first-page":"728","article-title":"Update on burkitt lymphoma and leukemia","volume":"7","author":"Hoelzer D.","year":"2009","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.25008","article-title":"Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies","volume":"116","author":"Jabbour E.","year":"2005","journal-title":"Cancer"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-043646"},{"key":"e_1_2_8_23_1","first-page":"181","volume-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.","year":"2001"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200409000-00003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.060"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2186"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000141301"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02068.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood.V63.5.1102.1102","article-title":"An effective therapy for both undifferentiated (including Burkitt\u2019s) lymphomas and lymphoblastic lymphomas in children and young adults","volume":"63","author":"Magrath I.T.","year":"1984","journal-title":"Blood"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0728-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08447.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.9861"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00681.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.341"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20143"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V116.21.858.858","article-title":"Efficacy and toxicity of Rituximab and brief duration, high intensity chemotherapy with Filgrastim support in Burkitt or Burkitt\/like Leukemia\/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002","volume":"116","author":"Rizzieri D.A.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02710168"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8385"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.677"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh262"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24922"},{"key":"e_1_2_8_47_1","first-page":"262","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2461"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.593274"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.120"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08947.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08947.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:59:42Z","timestamp":1697392782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08947.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,21]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08947.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08947.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,21]]},"assertion":[{"value":"2011-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}